Inhibitor in Biological Technology

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... inhibitors and at least one other HCV protease inhibitor in development. In an initial Phase 1 study of ... in combination with nucleoside polymerase inhibitor R7128, but no interferon or ribavirin, in ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

... including CUDC-305, the company's lead Hsp90 inhibitor candidate. Under the terms of the ... CUDC-101, our first-in-class HDAC/EGFR/Her2 inhibitor that is currently enrolling patients in a Phase I ... fund our further investment in our multi-targeted inhibitor programs, including CUDC-101." "Debiopharm ...

Sunesis Reports Financial Results for the Second Quarter 2009

... BIIB ) for the selection of a Raf kinase inhibitor development candidate for the treatment of ... co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration. On July ... and $1.5 million for the Biogen Idec Raf kinase inhibitor milestone referred to above. Revenues in the 2008 ...

Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results

... the first kilogram of its lead protease inhibitor drug candidate and has initiated 28-day chronic ... applications from our non-nucleoside polymerase inhibitor and protease inhibitor programs. These efforts will take us closer to ...

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

... SPC3649 is a potent and specific inhibitor of microRNA-122 known to be involved in ... results of the jointly developed Hif-1alpha inhibitor targeting solid tumors at the AACR meeting in ... Survivin targeting cancer. SPC4955-ApoB inhibitor Santaris Pharma has in rodent and primate ...

Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

... market. World market for small molecule kinase inhibitor drugs is projected to reach $16.2 billion by the ... tumor cell resistance to single targeted kinase inhibitor drugs is fingered as the key reason triggering ... new market research report. New generation kinase inhibitor drugs like Nexavar are forecast to witness ...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

... Application (sBLA) for Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute attacks of ... disease." About Cinryze(TM) (C1 esterase inhibitor [human]) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by FDA for routine ...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

... AT-101 AT-101 is an orally-active, pan-Bcl-2 inhibitor (including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 ... is an orally-active small molecule pan Bcl-2 inhibitor (Bcl-2, Bcl-xL, and Mcl-1) currently in Phase 2 ... oral multi-IAP antagonist AT-406, and an HDM2-p53 inhibitor program. For additional information on ...

Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... of the phosphoinositide-3-kinase (PI-3 kinase) inhibitor PX-866 in patients with advanced malignancy, and ... from two Phase 1b trials of the thioredoxin inhibitor PX-12 in advanced cancer patients. Stimuvax ... Oncothyreon's ongoing Phase 1 trial of PX-866, an inhibitor of PI-3 kinase, were presented by Dr. Antonio ...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

... for its work in bringing Cinryze(TM) (C1 esterase inhibitor (human)) to market for a rare and devastating ... a human plasma protein. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, ... for this therapy." Cinryze (C1 esterase inhibitor (human)) was approved by the U.S. Food and Drug ...

First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418

... GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that ... "This is the first geranylgeranyltransferase inhibitor to move to clinical phase studies," stated ... GGTI-2418 is a synthetic peptidomimetic inhibitor of GGTase I that appears to induce apoptosis by ...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

... first-ever combination of a nucleoside polymerase inhibitor and protease inhibitor in the absence of interferon in patients infected ... in combination with nucleoside polymerase inhibitor R7128 but no interferon or ribavirin in patients ...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

... Million in Net Sales of Cinryze(TM) C1 Esterase inhibitor (Human) - EXTON, Pa., April 29 ... million in net sales of Cinryze(TM) (C1 esterase inhibitor [human]); Working capital of $301 million ... commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... an investigational oral non-nucleoside polymerase inhibitor that Anadys is developing for the treatment of ... of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also ...

Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver

... IDX184, a once-daily, oral nucleotide polymerase inhibitor prodrug currently being evaluated in a phase ... candidates: IDX375, a non-nucleoside polymerase inhibitor and IDX316, a protease inhibitor, both currently ... IDX184 Nucleotide Prodrug Polymerase inhibitor IDX184 is a liver-targeted, oral nucleotide ...

INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

... that the innovative clinical study of protease inhibitor ITMN-191 (R7227) in combination with nucleoside polymerase inhibitor R7128 (Roche/Pharmasset), referred to as the ... is developing ITMN-191 (R7227), an HCV protease inhibitor compound to be used in combination with ...

AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting

... "AEZS-126, a new orally bioavailable PI3K inhibitor with antitumor effects", I. Seipelt, S. Baasner, ... Results AEZS-126 was identified as a potent inhibitor of class I PI3Ks in biochemical and cellular ... an IC50 value of 10nM and proved to be a potent inhibitor of Akt phosphorylation in cellular assays. ...

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

... was a clinical developer of the proteasome inhibitor VELCADE(R) at Millennium Pharmaceuticals (now a ... Proteolix's lead anti-cancer proteasome inhibitor for the treatment of multiple myeloma and other ... of Proteolix's earlier-stage proteasome inhibitor programs, including PR-047, an oral ...

AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting

... that it will present two posters on its PI3K inhibitor compound, AEZS-126, as well as a poster on its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, at the American Association ... "AEZS-126, a new orally bioavailable PI3K inhibitor with antitumor effects", I. Seipelt, S. ...

InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting

... Combination of the NS3/4A Protease inhibitor ITMN-191 with the Allosteric NS5B Polymerase inhibitor ITMN-8020 Enhances Replicon Clearance and Reduces ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...

INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)

... ITMN-191 (R7227) in combination with polymerase inhibitor R7128 (Roche/Pharmasset), referred to as the ... Antiviral Activity with a Nucleoside Polymerase inhibitor (R7128) and Protease (R7227/ITMN-191) inhibitor Combination in HCV: Safety, Pharmacokinetics and ...

FDA Accepts IND for Arno Therapeutics' Pan-DAC / Akt Inhibitor, AR-42

... histones and other molecules, and is a targeted inhibitor of the Pan-DAC and Akt pathways. HDAC inhibitors ... a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway undergoing ... studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways. For more ...

FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418

... for the Company's geranylgeranyltransferase inhibitor (GGTI-2418) has been accepted by the U.S. Food ... of 2009. GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that ... This is the first geranylgeranyltransferase inhibitor to move to clinical phase studies." Tigris ...

InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights

... plan and key milestones for its protease inhibitor ITMN-191, being developed in collaboration ... is working to name a second-generation protease inhibitor under the Roche/InterMune collaboration. Roche ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results

... -- Quarter Highlighted by Cinryze(TM) [C1 inhibitor (human)] Commercial Launch -- EXTON, Pa., ... of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the ... become effective for any third party's human C1 inhibitor product by October 21, 2010. The second CVR ...

InterMune Announces Issuance of U.S. Patent for ITMN-191

... term extends to October 13, 2024. ITMN-191 is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program ...

Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results

... of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human ... study of IDX184, its lead nucleotide polymerase inhibitor for the treatment of hepatitis C, and advanced ... for its lead HCV non-nucleoside polymerase inhibitor and HCV ...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

... for a phase 2b trial with R7128, a nucleoside inhibitor of HCV, slated to initiate in the first calendar ... filed an IND for PSI-7851, a nucleotide inhibitor of HCV, with the FDA and expects to initiate a ... 1 studies with its second generation nucleotide inhibitor for HCV, PSI-7851 in the first quarter of 2009. ...

Tigris Pharmaceuticals Files IND Application for GGTI-2418

... GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that ... This will be the first geranylgeranyltransferase inhibitor in human clinical trials in this well-validated ... GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that ...

FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD

... First proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) ... (30 mg and 60 mg) is the first proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) ... the development code TAK-390MR, is a proton pump inhibitor (PPI), which decreases acid production by turning ...

Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients

... for a phase 2b trial with R7128, a nucleoside inhibitor of hepatitis C (HCV), slated to initiate in the ... "R7128 is the most advanced nucleoside polymerase inhibitor in development and we believe this class of drug ... prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically ...

Purdue researcher invents molecule that stops SARS

... herpes and cancer, Ghosh said. "The molecular inhibitor we developed is very potent against the SARS ... "This is the first design and discovery of an inhibitor for this class of proteins. We are hopeful that ... structure-based design. "The design of this inhibitor was a challenge because we did not know the ...

Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology

... and In Vitro Characterization of PR-047, An Oral inhibitor of the 20S Proteasome" (Abstract # 3671) at the ... "An effective and tolerable oral proteasome inhibitor would have the potential to provide the clinical ... inhibitors, including an oral proteasome inhibitor (PR-047) and a selective immunoproteasome ...

Presentation on Cytopia's JAK2 Inhibitor Program in Myeloproliferative Disorders

... /PRNewswire/ -- Data on Cytopia's (ASX: CYT) JAK2 inhibitor CYT387 will be presented at the 50th American ... Effects of CYT387, a Potent Novel JAK2 inhibitor on JAK2-V617F Induc e d MPD 7am US PST, ... kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative ...

Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting

... kinase (Syk) and its novel universal Factor Xa inhibitor antidote will be presented at the annual meeting ... December 6-9, 2008. Portola's Syk inhibitor program is focused on developing specific ... Portola is developing its universal Factor Xa inhibitor antidote to neutralize the effect of small ...

InterMune Reports Third Quarter 2008 Financial Results and Business Highlights

... programs, including its lead protease inhibitor for the treatment of patients chronically ... with the active moiety of polymerase inhibitor R7128 (Roche/Pharmasset) in a 14-day replicon ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...

Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes

... small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently undergoing Phase 3 clinical development ... and market. We believe that Phenomix' DPP-4 inhibitor is a valuable addition to the available ... Dutogliptin Dutogliptin is a small molecule inhibitor of the enzyme DPP-4. These inhibitors prevent ...

SuperGen to Present Data at EORTC-NCI-AACR

... of SGI-1776, an orally active Pim kinase inhibitor Oct 23 Abstract ... MP-470, a novel multi-targeted tyrosine kinase inhibitor targeting RAD 51 is not toxic to human primary ... vivo by SGI-1252, a potent small molecule JAK2 inhibitor Oct ...

InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting

... Genotype 1 Patients with the NS3/4A Protease inhibitor ITMN-191 Leads to Rapid Reductions in Plasma HCV ... Poster #1885: Combination of the NS3/4A Protease inhibitor ITMN-191 (R7227) with the Active Moiety of the ... hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) ...

Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference

... RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase ... a Phase 1 clinical trial and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is ... we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory ...